Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > ARCH $4,000,000 funding from the National Research Council

View:

Post by Riverfolk on Apr 08, 2023 8:41pm

ARCH $4,000,000 funding from the National Research Council

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program.

These include:

dose escalation studies;
costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial;
manufacturing new drug product supply to support future non-COVID human trials;
the non-COVID Phase II trials (such as a cardiac surgery associated acute kidney injury trial) to gather more human data to support future drug approval;
and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide.